Literature DB >> 22707276

Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract.

Magaly Zappa1, Mohamed Abdel-Rehim, Olivia Hentic, Marie-Pierre Vullierme, Philippe Ruszniewski, Valérie Vilgrain.   

Abstract

Presence of liver metastases in neuroendocrine tumors is a major factor altering both quality of life and prognosis. Surgery is recognized as the sole curative treatment. When it is not possible, radiological directed therapies are crucial, particularly in liver metastases from the small bowel. Thermal ablative therapies as radiofrequency ablation and microwave are alternative treatments alone or in combination with surgery. Hepatic artery embolization or chemoembolization, as radioembolization, has been shown to have good clinical, biochemical, and morphological responses when liver burden does not permit ablative therapies. However, technical issues are multiple and there is no randomized study to compare their efficacy. The choice of management depends on liver burden and metastases pattern, but also on origin of the primary tumor, tumor differentiation, and tumor proliferative activity. These patients should benefit of a multidisciplinary management to limit morbidity and mortality.

Entities:  

Mesh:

Year:  2012        PMID: 22707276     DOI: 10.1007/s11523-012-0219-8

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  63 in total

1.  ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.

Authors:  Marianne Pavel; Eric Baudin; Anne Couvelard; Eric Krenning; Kjell Öberg; Thomas Steinmüller; Martin Anlauf; Bertram Wiedenmann; Ramon Salazar
Journal:  Neuroendocrinology       Date:  2012-02-15       Impact factor: 4.914

Review 2.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

3.  Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up.

Authors:  Hizir Yakup Akyildiz; Jamie Mitchell; Mira Milas; Allan Siperstein; Eren Berber
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

4.  Cryotherapy for neuroendocrine liver metastases.

Authors:  J K Seifert; P J Cozzi; D L Morris
Journal:  Semin Surg Oncol       Date:  1998-03

5.  Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma.

Authors:  Y H Kim; J A Ajani; C H Carrasco; P Dumas; W Richli; D Lawrence; V Chuang; S Wallace
Journal:  Cancer Invest       Date:  1999       Impact factor: 2.176

6.  Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.

Authors:  Sanjay Gupta; James C Yao; Kamran Ahrar; Michael J Wallace; Frank A Morello; David C Madoff; Ravi Murthy; Marshall E Hicks; Jaffer A Ajani
Journal:  Cancer J       Date:  2003 Jul-Aug       Impact factor: 3.360

7.  Prognostic variables in patients with gastrointestinal carcinoid tumours.

Authors:  E W McDermott; B Guduric; M F Brennan
Journal:  Br J Surg       Date:  1994-07       Impact factor: 6.939

8.  Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

Authors:  P Ruszniewski; P Rougier; A Roche; P Legmann; A Sibert; S Hochlaf; M Ychou; M Mignon
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

Review 9.  Neuroendocrine tumors: role of interventional radiology in therapy.

Authors:  Michael J Steward; Victoria S Warbey; Anmol Malhotra; Martyn E Caplin; John R Buscombe; Dominic Yu
Journal:  Radiographics       Date:  2008 Jul-Aug       Impact factor: 5.333

10.  Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver.

Authors:  D Elias; D Goéré; G Leroux; C Dromain; S Leboulleux; Th de Baere; M Ducreux; E Baudin
Journal:  Eur J Surg Oncol       Date:  2009-05-21       Impact factor: 4.424

View more
  13 in total

1.  New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?

Authors:  Eric Raymond; Philippe Ruszniewski
Journal:  Target Oncol       Date:  2012-06-05       Impact factor: 4.493

2.  Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Yusuf Menda; Donghong Wang; Thomas M O'Dorisio; James R Howe
Journal:  J Surg Res       Date:  2014-05-21       Impact factor: 2.192

Review 3.  Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.

Authors:  Romain Coriat; Thomas Walter; Benoît Terris; Anne Couvelard; Philippe Ruszniewski
Journal:  Oncologist       Date:  2016-07-08

Review 4.  Update in the Therapy of Advanced Neuroendocrine Tumors.

Authors:  Inbal Uri; Shani Avniel-Polak; David J Gross; Simona Grozinsky-Glasberg
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

5.  Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Authors:  Allen B Choi; Jessica E Maxwell; Kendall J Keck; Andrew J Bellizzi; Joseph S Dillon; Thomas M OʼDorisio; James R Howe
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

6.  Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract.

Authors:  William E Gibson; Raul S Gonzalez; Justin M M Cates; Eric Liu; Chanjuan Shi
Journal:  Hum Pathol       Date:  2018-05-12       Impact factor: 3.466

7.  Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution.

Authors:  Eric S Engelman; Roberto Leon-Ferre; Boris G Naraev; Nancy Sharma; Shiliang Sun; Thomas M O'Dorisio; James Howe; Anna Button; Gideon Zamba; Thorvardur R Halfdanarson
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

Review 8.  Liver transarterial embolizations in metastatic neuroendocrine tumors.

Authors:  Louis de Mestier; Magaly Zappa; Olivia Hentic; Valérie Vilgrain; Philippe Ruszniewski
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

9.  Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer.

Authors:  Marjorie Faure; Patricia Niccoli; Aurelie Autret; Gerard Cavaglione; Laurent Mineur; Jean-Luc Raoul
Journal:  Mol Clin Oncol       Date:  2016-12-01

Review 10.  Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions.

Authors:  Anna Pellat; Anne Ségolène Cottereau; Lola-Jade Palmieri; Philippe Soyer; Ugo Marchese; Catherine Brezault; Romain Coriat
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.